Cargando…

Tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma

Head and neck squamous cell carcinomas (HNSCCs) are a type of common malignant tumor, mainly manifesting as oropharyngeal, oral cavity, laryngopharyngeal, hypopharyngeal, and laryngeal cancers. These highly aggressive malignant tumors reportedly affect more than 830,000 patients worldwide every year...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Yixiao, Zheng, Xiwang, Gao, Wei, Wang, Binquan, Wu, Yongyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878981/
https://www.ncbi.nlm.nih.gov/pubmed/33614915
http://dx.doi.org/10.1016/j.omto.2021.01.011
_version_ 1783650437755305984
author Qin, Yixiao
Zheng, Xiwang
Gao, Wei
Wang, Binquan
Wu, Yongyan
author_facet Qin, Yixiao
Zheng, Xiwang
Gao, Wei
Wang, Binquan
Wu, Yongyan
author_sort Qin, Yixiao
collection PubMed
description Head and neck squamous cell carcinomas (HNSCCs) are a type of common malignant tumor, mainly manifesting as oropharyngeal, oral cavity, laryngopharyngeal, hypopharyngeal, and laryngeal cancers. These highly aggressive malignant tumors reportedly affect more than 830,000 patients worldwide every year. Currently, the main treatments for HNSCC include surgery, radiotherapy, chemotherapy, and immunotherapy, as well as combination therapy. However, the overall 5-year survival rate of HNSCC has remained 50%, and it has not significantly improved in the past 10 years. Previous studies have shown that the tumor microenvironment (TME) plays a crucial role in the recurrence, metastasis, and drug resistance of patients with HNSCC. In this review, we summarize the role of anti-tumor and pro-tumor immune cells, as well as extracellular components in the TME of HNSCC. We also discuss classical HNSCC immunotherapy and highlight examples of clinical trials using CTLA-4 inhibitors and programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1)-related combination therapies. We also outline some molecules in the TME known to regulate immunosuppressive cells. Furthermore, the role and underlying mechanism of radiation therapy on the TME, immune cells, and immune response are discussed.
format Online
Article
Text
id pubmed-7878981
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society of Gene & Cell Therapy
record_format MEDLINE/PubMed
spelling pubmed-78789812021-02-19 Tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma Qin, Yixiao Zheng, Xiwang Gao, Wei Wang, Binquan Wu, Yongyan Mol Ther Oncolytics Review Head and neck squamous cell carcinomas (HNSCCs) are a type of common malignant tumor, mainly manifesting as oropharyngeal, oral cavity, laryngopharyngeal, hypopharyngeal, and laryngeal cancers. These highly aggressive malignant tumors reportedly affect more than 830,000 patients worldwide every year. Currently, the main treatments for HNSCC include surgery, radiotherapy, chemotherapy, and immunotherapy, as well as combination therapy. However, the overall 5-year survival rate of HNSCC has remained 50%, and it has not significantly improved in the past 10 years. Previous studies have shown that the tumor microenvironment (TME) plays a crucial role in the recurrence, metastasis, and drug resistance of patients with HNSCC. In this review, we summarize the role of anti-tumor and pro-tumor immune cells, as well as extracellular components in the TME of HNSCC. We also discuss classical HNSCC immunotherapy and highlight examples of clinical trials using CTLA-4 inhibitors and programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1)-related combination therapies. We also outline some molecules in the TME known to regulate immunosuppressive cells. Furthermore, the role and underlying mechanism of radiation therapy on the TME, immune cells, and immune response are discussed. American Society of Gene & Cell Therapy 2021-01-21 /pmc/articles/PMC7878981/ /pubmed/33614915 http://dx.doi.org/10.1016/j.omto.2021.01.011 Text en © 2021 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Qin, Yixiao
Zheng, Xiwang
Gao, Wei
Wang, Binquan
Wu, Yongyan
Tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma
title Tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma
title_full Tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma
title_fullStr Tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma
title_full_unstemmed Tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma
title_short Tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma
title_sort tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878981/
https://www.ncbi.nlm.nih.gov/pubmed/33614915
http://dx.doi.org/10.1016/j.omto.2021.01.011
work_keys_str_mv AT qinyixiao tumormicroenvironmentandimmunerelatedtherapiesofheadandnecksquamouscellcarcinoma
AT zhengxiwang tumormicroenvironmentandimmunerelatedtherapiesofheadandnecksquamouscellcarcinoma
AT gaowei tumormicroenvironmentandimmunerelatedtherapiesofheadandnecksquamouscellcarcinoma
AT wangbinquan tumormicroenvironmentandimmunerelatedtherapiesofheadandnecksquamouscellcarcinoma
AT wuyongyan tumormicroenvironmentandimmunerelatedtherapiesofheadandnecksquamouscellcarcinoma